<?xml version='1.0' encoding='utf-8'?>
<document id="10778943"><sentence text="Clinical pharmacokinetics of oxaliplatin: a critical review."><entity charOffset="29-40" id="DDI-PubMed.10778943.s1.e0" text="oxaliplatin" /></sentence><sentence text="Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N'] oxalato(2-)-O,O'] platinum; Eloxatine) is a novel platinum coordination complex used for the treatment of metastatic colorectal carcinoma in combination with fluoropyrimidines"><entity charOffset="0-11" id="DDI-PubMed.10778943.s2.e0" text="Oxaliplatin" /><entity charOffset="13-81" id="DDI-PubMed.10778943.s2.e1" text="cis-[(1R,2R)-1,2-cyclohexanediamine-N,N'] oxalato(2-)-O,O'] platinum" /><entity charOffset="83-92" id="DDI-PubMed.10778943.s2.e2" text="Eloxatine" /><entity charOffset="105-113" id="DDI-PubMed.10778943.s2.e3" text="platinum" /><entity charOffset="213-230" id="DDI-PubMed.10778943.s2.e4" text="fluoropyrimidines" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e0" e2="DDI-PubMed.10778943.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e0" e2="DDI-PubMed.10778943.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e0" e2="DDI-PubMed.10778943.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e0" e2="DDI-PubMed.10778943.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e0" e2="DDI-PubMed.10778943.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e1" e2="DDI-PubMed.10778943.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e1" e2="DDI-PubMed.10778943.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e1" e2="DDI-PubMed.10778943.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e1" e2="DDI-PubMed.10778943.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e2" e2="DDI-PubMed.10778943.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e2" e2="DDI-PubMed.10778943.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e2" e2="DDI-PubMed.10778943.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e3" e2="DDI-PubMed.10778943.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10778943.s2.e3" e2="DDI-PubMed.10778943.s2.e4" /></sentence><sentence text=" The objective of this review is to integrate the key data from multiple studies into a single, comprehensive overview of oxaliplatin disposition in cancer patients"><entity charOffset="122-133" id="DDI-PubMed.10778943.s3.e0" text="oxaliplatin" /></sentence><sentence text=" The pharmacokinetics (PKs) of unbound platinum in plasma ultrafiltrate after oxaliplatin administration was triphasic, characterized by a short initial distribution phase and a long terminal elimination phase (t1/2, 252-273 h)"><entity charOffset="39-47" id="DDI-PubMed.10778943.s4.e0" text="platinum" /><entity charOffset="78-89" id="DDI-PubMed.10778943.s4.e1" text="oxaliplatin" /><pair ddi="false" e1="DDI-PubMed.10778943.s4.e0" e2="DDI-PubMed.10778943.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10778943.s4.e0" e2="DDI-PubMed.10778943.s4.e1" /></sentence><sentence text=" No accumulation was observed in plasma ultrafiltrate after 130 mg/m2 every 3 weeks or 85 mg/m2 every 2 weeks" /><sentence text=" Interpatient and intrapatient variability in platinum exposure (area under the curve(0-48)) is moderate to low (33 and 5% respectively)"><entity charOffset="46-54" id="DDI-PubMed.10778943.s6.e0" text="platinum" /></sentence><sentence text=" In the blood, platinum binds irreversibly to plasma proteins (predominantly serum albumin) and erythrocytes"><entity charOffset="15-23" id="DDI-PubMed.10778943.s7.e0" text="platinum" /></sentence><sentence text=" Accumulation of platinum in blood cells is not considered to be clinically significant"><entity charOffset="17-25" id="DDI-PubMed.10778943.s8.e0" text="platinum" /></sentence><sentence text=" Platinum is rapidly cleared from plasma by covalent binding to tissues and renal elimination"><entity charOffset="1-9" id="DDI-PubMed.10778943.s9.e0" text="Platinum" /></sentence><sentence text=" Urinary excretion (53" /><sentence text="8 +/- 9" /><sentence text="1%) was the predominant route of platinum elimination, with fecal excretion accounting for only 2"><entity charOffset="33-41" id="DDI-PubMed.10778943.s12.e0" text="platinum" /></sentence><sentence text="1 +/- 1" /><sentence text="9% of the administered dose 5 days postadministration" /><sentence text=" Tissue binding and renal elimination contribute equally to the clearance of ultrafilterable platinum from plasma"><entity charOffset="93-101" id="DDI-PubMed.10778943.s15.e0" text="platinum" /></sentence><sentence text=" Renal clearance of platinum significantly correlated with glomerular filtration rate, indicating that glomerular filtration is the principal mechanism of platinum elimination by the kidneys"><entity charOffset="20-28" id="DDI-PubMed.10778943.s16.e0" text="platinum" /><entity charOffset="155-163" id="DDI-PubMed.10778943.s16.e1" text="platinum" /><pair ddi="false" e1="DDI-PubMed.10778943.s16.e0" e2="DDI-PubMed.10778943.s16.e0" /><pair ddi="false" e1="DDI-PubMed.10778943.s16.e0" e2="DDI-PubMed.10778943.s16.e1" /></sentence><sentence text=" Clearance of ultrafilterable platinum is lower in patients with moderate renal impairment; however, no marked increase in drug toxicity was reported"><entity charOffset="30-38" id="DDI-PubMed.10778943.s17.e0" text="platinum" /></sentence><sentence text=" The effect of severe renal impairment on platinum clearance and toxicity is currently unknown"><entity charOffset="42-50" id="DDI-PubMed.10778943.s18.e0" text="platinum" /></sentence><sentence text=" Covariates such as age, sex, and hepatic impairment had no significant effect on the clearance of ultrafilterable platinum, and dose adjustment due to these variables is not required"><entity charOffset="115-123" id="DDI-PubMed.10778943.s19.e0" text="platinum" /></sentence><sentence text=" Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation and is not subjected to CYP450-mediated metabolism"><entity charOffset="1-12" id="DDI-PubMed.10778943.s20.e0" text="Oxaliplatin" /></sentence><sentence text=" Up to 17 platinum-containing products have been observed in plasma ultrafiltrate samples from patients"><entity charOffset="10-18" id="DDI-PubMed.10778943.s21.e0" text="platinum" /></sentence><sentence text=" These include several proximate cytotoxic species, including the monochloro-, dichloro-, and diaquo-diaminocyclohexane platinum complexes, along with several other noncytotoxic products"><entity charOffset="66-77" id="DDI-PubMed.10778943.s22.e0" text="monochloro-" /><entity charOffset="79-88" id="DDI-PubMed.10778943.s22.e1" text="dichloro-" /><entity charOffset="94-128" id="DDI-PubMed.10778943.s22.e2" text="diaquo-diaminocyclohexane platinum" /><pair ddi="false" e1="DDI-PubMed.10778943.s22.e0" e2="DDI-PubMed.10778943.s22.e0" /><pair ddi="false" e1="DDI-PubMed.10778943.s22.e0" e2="DDI-PubMed.10778943.s22.e1" /><pair ddi="false" e1="DDI-PubMed.10778943.s22.e0" e2="DDI-PubMed.10778943.s22.e2" /><pair ddi="false" e1="DDI-PubMed.10778943.s22.e1" e2="DDI-PubMed.10778943.s22.e1" /><pair ddi="false" e1="DDI-PubMed.10778943.s22.e1" e2="DDI-PubMed.10778943.s22.e2" /></sentence><sentence text=" Oxaliplatin does not inhibit CYP450 isoenzymes in vitro"><entity charOffset="1-12" id="DDI-PubMed.10778943.s23.e0" text="Oxaliplatin" /></sentence><sentence text=" Platinum was not displaced from plasma proteins by a variety of concomitant medications tested in vitro, and no marked PK interactions between oxaliplatin, 5-fluorouracil, and irinothecan have been observed"><entity charOffset="1-9" id="DDI-PubMed.10778943.s24.e0" text="Platinum" /><entity charOffset="144-155" id="DDI-PubMed.10778943.s24.e1" text="oxaliplatin" /><entity charOffset="157-171" id="DDI-PubMed.10778943.s24.e2" text="5-fluorouracil" /><pair ddi="false" e1="DDI-PubMed.10778943.s24.e0" e2="DDI-PubMed.10778943.s24.e0" /><pair ddi="false" e1="DDI-PubMed.10778943.s24.e0" e2="DDI-PubMed.10778943.s24.e1" /><pair ddi="false" e1="DDI-PubMed.10778943.s24.e0" e2="DDI-PubMed.10778943.s24.e2" /><pair ddi="false" e1="DDI-PubMed.10778943.s24.e1" e2="DDI-PubMed.10778943.s24.e1" /><pair ddi="false" e1="DDI-PubMed.10778943.s24.e1" e2="DDI-PubMed.10778943.s24.e2" /></sentence><sentence text=" These results indicate that the additive/synergistic antitumor activity observed with these agents is not due to major alterations in drug exposure, and the enhanced efficacy is likely to be mechanistically based" /><sentence text=" Together, these PK, biotransformation, drug-drug interaction analyses and studies in special patient populations provide a firm scientific basis for the safe and effective use of oxaliplatin in the clinic"><entity charOffset="180-191" id="DDI-PubMed.10778943.s26.e0" text="oxaliplatin" /></sentence><sentence text=" These analyses also reveal that the pharmacological activity of oxaliplatin may be attributable, at least in part, to the unique pattern of platinum disposition observed in patients"><entity charOffset="65-76" id="DDI-PubMed.10778943.s27.e0" text="oxaliplatin" /><entity charOffset="141-149" id="DDI-PubMed.10778943.s27.e1" text="platinum" /><pair ddi="false" e1="DDI-PubMed.10778943.s27.e0" e2="DDI-PubMed.10778943.s27.e0" /><pair ddi="false" e1="DDI-PubMed.10778943.s27.e0" e2="DDI-PubMed.10778943.s27.e1" /></sentence><sentence text="" /></document>